- Sanofi SA (NASDAQ:SNY) shared the latest results from the Phase 3 IKEMA trial evaluating Sarclisa (isatuximab) in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy.
- Sarclisa combined with carfilzomib and dexamethasone (Kd) demonstrated a median progression-free survival (mPFS) of 35.7 months, compared to 19.2 months in patients treated with Kd alone.
- Following the FDA recommendations on censoring rules, the analysis showed an mPFS of 41.7 months for Sarclisa combination therapy compared to 20.8 months in patients treated with Kd alone.
- The time to next treatment for patients treated with Sarclisa combination therapy was 44.9 months versus those treated with Kd alone at 25 months.
- The safety and tolerability of Sarclisa observed in this analysis were consistent with the safety profile of Sarclisa in other clinical trials, with no new safety signals observed.
- Price Action: SNY shares are up 0.74% at $52.42 during the market session on the last check Monday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Sanofi Says Sarclisa Shows 'Unprecedented Median Progression-Free Survival' In Multiple Myeloma Patients
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks